MMAF (hydrochloride)

MMAF (hydrochloride)

• CAS Number: 1415246-68-2
• UNSPSC Description: MMAF (Monomethylauristatin F) hydrochloride is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A[1][2][3].
• Target Antigen: ADC Cytotoxin; Microtubule/Tubulin
• Type: ADC Related
• Related Pathways: Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/MMAF-Hydrochloride.html
• Solubility: DMSO : 25 mg/mL (ultrasonic)|H2O : ≥ 100 mg/mL
• Smiles: CC(C)[C@H](NC)C(N[C@H](C(N([C@@H]([C@@H](C)CC)[C@H](OC)CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)=O)C)=O)C(C)C)=O.Cl
• Molecular Weight: 768.42
• References & Citations: [1]Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.|[2]Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70.|[3]Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54(41):12020-4.|[4]Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted CancerTherapeutics.Oncol Rep. 2020 Dec 9.|J Control Release. 2018 May 10;277:48-56.|Mol Cancer Ther. 2023 Jan 31;MCT-22-0440.|Mol Ther Nucleic Acids. 2018 Mar 2;10:227-236.|Patent. US20210393733A1.|Research Square Preprint. 2023 Dec 4.|Research Square Print. 2023 Jan 6th.|Target Oncol. 2019 Oct;14(5):577-590.|University of Minnesota. 2022 Sep.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported